Загрузка...
Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD
BACKGROUND: The oral selective phosphodiesterase-4 inhibitor roflumilast (ROF) reduces exacerbations in patients with severe COPD. Adverse events (AEs) can cause early ROF discontinuation. Alternative dosing strategies may help patients continue their therapy. METHODS: In this multicenter, double-bl...
Сохранить в:
| Опубликовано в: : | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5846760/ https://ncbi.nlm.nih.gov/pubmed/29563781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S154012 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|